NASDAQ:ANIK Anika Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Anika Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $22.51 +0.32 (+1.44%) (As of 06/29/2022 12:00 AM ET) Add Compare Share Today's Range$21.97▼$22.8050-Day Range$20.40▼$23.5052-Week Range$19.95▼$45.81Volume79,822 shsAverage Volume98,721 shsMarket Capitalization$327.39 millionP/E RatioN/ADividend YieldN/APrice Target$43.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ANIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIK Stock Forecast (MarketRank)Overall MarketRank™2.27 out of 5 starsMedical Sector310th out of 1,432 stocksSurgical & Medical Instruments Industry37th out of 137 stocksAnalyst Opinion: 3.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 - 3.0 Analyst's Opinion Consensus RatingAnika Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $43.00, Anika Therapeutics has a forecasted upside of 91.0% from its current price of $22.51.Amount of Analyst CoverageAnika Therapeutics has received no research coverage in the past 90 days. Previous Next 4.4 Community Rank Outperform VotesAnika Therapeutics has received 293 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAnika Therapeutics has received 155 “underperform” votes. (Add your “underperform” vote.)Community SentimentAnika Therapeutics has received 65.40% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote “Outperform” if you believe ANIK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ANIK will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAnika Therapeutics does not currently pay a dividend.Dividend GrowthAnika Therapeutics does not have a long track record of dividend growth. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anika Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $32,055.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.03% of the stock of Anika Therapeutics is held by insiders.Percentage Held by Institutions93.24% of the stock of Anika Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Anika Therapeutics are expected to grow in the coming year, from ($0.55) to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anika Therapeutics is -204.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anika Therapeutics is -204.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnika Therapeutics has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Anika Therapeutics (NASDAQ:ANIK)Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.Read More ANIK Stock News HeadlinesJune 4, 2022 | finance.yahoo.comInsights on the Sodium Hyaluronate-based Products Global Market to 2030 - Featuring Allergan, Cadila Pharmaceuticals and Galderma Among OthersMay 31, 2022 | benzinga.comWorldwide Viscosupplementation Industry to 2027 - Players Include Sanofi, Anika Therapeutics and Zimmer Biomet Among OthersMay 23, 2022 | marketwatch.comHyaluronic Acid Based Dermal Fillers Market Size 2022 Research Findings, Market Growth Factors Analysis and Forecasts – 2026May 21, 2022 | morningstar.comAnika Therapeutics Gets FDA OK for X-Twist Knotless Fixation SystemMay 20, 2022 | benzinga.comNew FDA 510(k) Clearance Expands Anika's Sports Medicine Soft Tissue PortfolioMay 20, 2022 | seekingalpha.comAnika gets FDA clearance for X-Twist Knotless Fixation SystemMay 20, 2022 | finance.yahoo.comAnika Receives FDA 510(k) Clearance for the X-Twist™ Knotless Fixation System, Expanding its Sports Medicine Soft Tissue PortfolioMay 10, 2022 | finance.yahoo.comAnika Therapeutics (NASDAQ:ANIK) shareholders have endured a 56% loss from investing in the stock five years agoMay 9, 2022 | finance.yahoo.comAnika to Participate in the UBS Global Healthcare Conference 2022May 7, 2022 | seekingalpha.comAnika Therapeutics, Inc. (ANIK) CEO Cheryl Blanchard on Q1 2022 Results - Earnings Call TranscriptMay 4, 2022 | seekingalpha.comAnika Therapeutics Q1 2022 Earnings PreviewMay 4, 2022 | finance.yahoo.comTechne (TECH) Beats Q3 Earnings and Revenue EstimatesApril 22, 2022 | benzinga.comGlobal Orthopedic Hyaluronic Acid Market to 2027 - Featuring Allergan, Anika Therapeutics and Galderma Among Others - ResearchAndMarkets.comSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:ANIK CUSIP03525510 CIK898437 Webwww.anikatherapeutics.com Phone(781) 457-9000Fax781-305-9720Employees297Year Founded1992Company Calendar Last Earnings5/05/2022Today6/29/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$43.00 High Stock Price Forecast$48.00 Low Stock Price Forecast$35.00 Forecasted Upside/Downside+91.0%Consensus RatingHold Rating Score (0-4)2 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.110010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$4.13 million Net Margins-1.09% Pretax Margin-1.66% Return on Equity-0.92% Return on Assets-0.75% Debt Debt-to-Equity RatioN/A Current Ratio6.12 Quick Ratio4.82 Sales & Book Value Annual Sales$147.79 million Price / Sales2.22 Cash Flow$1.41 per share Price / Cash Flow15.94 Book Value$19.89 per share Price / Book1.13Miscellaneous Outstanding Shares14,544,000Free Float14,103,000Market Cap$327.39 million OptionableOptionable Beta1.11 Social Links Anika Therapeutics Frequently Asked Questions Should I buy or sell Anika Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Anika Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANIK, but not buy additional shares or sell existing shares. View analyst ratings for Anika Therapeutics or view top-rated stocks. What is Anika Therapeutics' stock price forecast for 2022? 3 brokerages have issued 12-month price objectives for Anika Therapeutics' shares. Their ANIK stock forecasts range from $35.00 to $48.00. On average, they anticipate Anika Therapeutics' stock price to reach $43.00 in the next year. This suggests a possible upside of 91.0% from the stock's current price. View analysts' price targets for Anika Therapeutics or view top-rated stocks among Wall Street analysts. How has Anika Therapeutics' stock price performed in 2022? Anika Therapeutics' stock was trading at $35.83 at the start of the year. Since then, ANIK stock has decreased by 37.2% and is now trading at $22.51. View the best growth stocks for 2022 here. When is Anika Therapeutics' next earnings date? Anika Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Anika Therapeutics. How were Anika Therapeutics' earnings last quarter? Anika Therapeutics, Inc. (NASDAQ:ANIK) posted its earnings results on Thursday, May, 5th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.13. The biotechnology company earned $36.69 million during the quarter, compared to analysts' expectations of $33.90 million. Anika Therapeutics had a negative trailing twelve-month return on equity of 0.92% and a negative net margin of 1.09%. During the same quarter in the prior year, the business posted $0.06 earnings per share. View Anika Therapeutics' earnings history. Who are Anika Therapeutics' key executives? Anika Therapeutics' management team includes the following people: Dr. Cheryl Renee Blanchard Ph.D., Pres, CEO & Director (Age 58, Pay $1.26M)Mr. Michael L. Levitz, Exec. VP, CFO & Treasurer (Age 48, Pay $683.14k) (LinkedIn Profile)Mr. David Colleran, Exec. VP, Gen. Counsel & Corp. Sec. (Age 50, Pay $649.06k)Ms. Anne Nunes, VP of OperationsMr. Mark Namaroff, Exec. Director of Investor Relations & Corp. Communications (Age 59)Mr. Charles Sherwood III, VP & Corp. Legal CounselMr. James Chase, Sr. VP of International Sales & MarketingMr. Bart Bracy, VP of Sales & Marketing of AmericasMr. Ben Joseph, VP of Commercial & Corp. Devel.Ms. Lisa Funiciello, VP of HR Who are some of Anika Therapeutics' key competitors? Some companies that are related to Anika Therapeutics include West Pharmaceutical Services (WST), Align Technology (ALGN), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), QuidelOrtho (QDEL), ICU Medical (ICUI), STAAR Surgical (STAA), Haemonetics (HAE), Merit Medical Systems (MMSI), Neogen (NEOG), Meridian Bioscience (VIVO), Atrion (ATRI), Antares Pharma (ATRS), Cerus (CERS) and Utah Medical Products (UTMD). View all of ANIK's competitors. What other stocks do shareholders of Anika Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND). What is Anika Therapeutics' stock symbol? Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK." How do I buy shares of Anika Therapeutics? Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Anika Therapeutics' stock price today? One share of ANIK stock can currently be purchased for approximately $22.51. How much money does Anika Therapeutics make? Anika Therapeutics (NASDAQ:ANIK) has a market capitalization of $327.39 million and generates $147.79 million in revenue each year. The biotechnology company earns $4.13 million in net income (profit) each year or ($0.110010) on an earnings per share basis. How many employees does Anika Therapeutics have? Anika Therapeutics employs 297 workers across the globe. When was Anika Therapeutics founded? Anika Therapeutics was founded in 1992. How can I contact Anika Therapeutics? Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for Anika Therapeutics is www.anikatherapeutics.com. The biotechnology company can be reached via phone at (781) 457-9000, via email at [email protected], or via fax at 781-305-9720. This page (NASDAQ:ANIK) was last updated on 6/30/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here